Press Release

PHILADELPHIA, Pennsylvania, December 2 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialtybiopharmaceutical company, announces that it has settled the litigation withTeva Pharmaceuticals USA, Inc. ("Teva") over Shire's supply to Teva of anauthorized generic version of ADDERALL XR. Shire has been supplying Teva withauthorized generic ADDERALL XR since April 1, 2009. Shire's ability to supplythe product had been limited by restrictions that the US Drug EnforcementAdministration ("DEA") places on amphetamine, which is the product's activeingredient. Teva filed suit claiming that Shire was in breach of its supplycontract. After the lawsuit was filed, DEA granted Shire additional quota for2009, allowing Shire to supply Teva with additional product.

Teva has now dismissed its lawsuit, including its claims for monetarydamages, specific performance and other equitable relief. No considerationwas exchanged by the parties as part of the settlement.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialtybiopharmaceutical company that focuses on meeting the needs of the specialistphysician. Shire focuses its business on attention deficit hyperactivitydisorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)diseases as well as opportunities in other therapeutic areas to the extentthey arise through acquisitions. Shire's in-licensing, merger and acquisitionefforts are focused on products in specialist markets with strongintellectual property protection and global rights. Shire believes that acarefully selected and balanced portfolio of products with strategicallyaligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORMACT OF 1995

Statements included herein that are not historical facts areforward-looking statements. Such forward-looking statements involve a numberof risks and uncertainties and are subject to change at any time. In theevent such risks or uncertainties materialize, the Company's results could bematerially adversely affected. The risks and uncertainties include, but arenot limited to, risks associated with: the inherent uncertainty of research,development, approval, reimbursement, manufacturing and commercialization ofthe Company's Specialty Pharmaceutical and Human Genetic Therapies products,as well as the ability to secure and integrate new products forcommercialization and/or development; government regulation of the Company'sproducts; the Company's ability to manufacture its products in sufficientquantities to meet demand; the impact of competitive therapies on theCompany's products; the Company's ability to register, maintain and enforcepatents and other intellectual property rights relating to its products; theCompany's ability to obtain and maintain government and other third-partyreimbursement for its products; and other risks and uncertainties detailedfrom time to time in the Company's filings with the Securities and ExchangeCommission.